Russian pharmaceutical companies: scientifi c R&D evaluation methods as a factor of competitiveness in the context of pandemic

Abstract

The methods used in Russian accounting practices do not allow pharmaceutical companies to fully assess the intangible advantages that will allow them to compete in the market successfully. In accordance with the international approach, if proof of the effectiveness and safety of a new drug has already been obtained, the company can start including current costs in the cost of a new intangible asset as early as the third phase of research. As for the Russian rules, capitalization of development costs is possible only after execution of regulatory authority registration of a new drug.